Completed PHASE2 INTERVENTIONAL 1-arm NCT00075647

CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase II Trial of CCI-779 in Locally Advanced or Metastatic Pancreatic Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Adenocarcinoma of the Pancreas Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer

Interventions laboratory biomarker analysis temsirolimus

Updated 6 times since 2017 Last updated: Jan 16, 2013 Started: Dec 31, 2003 Primary completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00075647, this PHASE2 trial focuses on Adenocarcinoma of the Pancreas and Recurrent Pancreatic Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States